{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Recreational+Drug+Users", "query": { "condition": "Healthy Recreational Drug Users" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Recreational+Drug+Users&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T23:44:39.308Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03509285", "title": "A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Alprazolam Placebo", "type": "DRUG" }, { "name": "Cenobamate placebo", "type": "DRUG" }, { "name": "Alprazolam", "type": "DRUG" }, { "name": "Cenobamate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SK Life Science, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 53, "start_date": "2017-03-08", "completion_date": "2017-12-15", "has_results": false, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03509285" }, { "nct_id": "NCT06097676", "title": "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abuse Potential" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Alprazolam 2 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbor Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 86, "start_date": "2021-09-28", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097676" }, { "nct_id": "NCT06453265", "title": "A Study to Assess the Abuse Potential of Intranasal Cebranopadol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Abuse, Drug" ], "interventions": [ { "name": "Cebranopadol- 600 ug", "type": "DRUG" }, { "name": "Cebranopadol- 800ug", "type": "DRUG" }, { "name": "Cebranopadol- 1000ug", "type": "DRUG" }, { "name": "Treatment A:", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Qualification", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tris Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2024-06-28", "completion_date": "2024-11-06", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06453265" }, { "nct_id": "NCT01438749", "title": "A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RO4917838", "type": "DRUG" }, { "name": "diazepam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 177, "start_date": "2011-10", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01438749" }, { "nct_id": "NCT01596673", "title": "A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Abuse" ], "interventions": [ { "name": "45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 100, "start_date": "2012-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-11-21", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596673" }, { "nct_id": "NCT05319756", "title": "Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abuse Potential" ], "interventions": [ { "name": "gabapentin 600 mg", "type": "DRUG" }, { "name": "gabapentin 1200 mg", "type": "DRUG" }, { "name": "gabapentin 600 mg and oxycodone HCl 20 mg", "type": "DRUG" }, { "name": "gabapentin 1200 mg and oxycodone HCl 20 mg", "type": "DRUG" }, { "name": "oxycodone HCl 20 mg", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viatris Specialty LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2021-04-30", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Marlton, New Jersey", "locations": [ { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319756" }, { "nct_id": "NCT05602818", "title": "A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Soticlestat 300 mg", "type": "DRUG" }, { "name": "Soticlestat 600 mg", "type": "DRUG" }, { "name": "Soticlestat 900 mg", "type": "DRUG" }, { "name": "Alprazolam", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 100, "start_date": "2022-11-15", "completion_date": "2023-07-07", "has_results": true, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602818" }, { "nct_id": "NCT02144415", "title": "A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Drug Users" ], "interventions": [ { "name": "EB-1020 400 mg", "type": "DRUG" }, { "name": "EB-1020 800 mg", "type": "DRUG" }, { "name": "lisdexamfetamine 150 mg", "type": "DRUG" }, { "name": "d-amphetamine 40 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 80, "start_date": "2014-05-01", "completion_date": "2014-07-01", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144415" }, { "nct_id": "NCT03657355", "title": "Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Recreational Drug Users" ], "interventions": [ { "name": "ACT-541468", "type": "DRUG" }, { "name": "Suvorexant", "type": "DRUG" }, { "name": "Zolpidem", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 63, "start_date": "2018-09-07", "completion_date": "2019-08-08", "has_results": false, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657355" }, { "nct_id": "NCT01825447", "title": "A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Oxycodone + Naltrexone", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 89, "start_date": "2013-07", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-10-08", "last_synced_at": "2026-07-23T23:44:39.308Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01825447" } ] }